Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine for Cognitive Dysfunction in Long-Covid
NCT06234462Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Jun 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in post-acute sequelae of SARS-CoV-2 infection (PASC) comparing Standard of Care with Standard of Care + Amantadine (2 arms). Primary endpoint: Measures of cognitive functioning at 4 weeks. Planned start Jun 2025; status: withdrawn.
02
Drugs
amantadine
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT06234462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234462.